Systemic mastocytosis associated with chronic idiopathic myelofibrosis: A distinct subtype of systemic mastocytosis-associated clonal hematological nonmast cell lineage disorder carrying the activating point mutations KIT D816V and JAK2V617F

Journal of Molecular Diagnostics

Volumn 10, Issue 1, 2008, Pages 58-66

  Sotlar, Karl ^a,e   Bache, Anja ^a   Stellmacher, Florian ^b   Bültmann, Burkhard ^a   Valent, Peter ^d   Horny, Hans Peter ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c Klinikum Ansbach   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD15 ANTIGEN; CD34 ANTIGEN; JANUS KINASE 2; STEM CELL FACTOR;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CARCINOGENESIS; CHRONIC DISEASE; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MAST CELL; MICRODISSECTION; MYELOID METAPLASIA; POINT MUTATION; SYSTEMIC MASTOCYTOSIS; SYSTEMIC MASTOCYTOSIS ASSOCIATED CLONAL HEMATOLOGICAL NONMAST CELL LINEAGE DISORDER;

EID: 38749092150     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2008.070061     Document Type: Article

References (36)

1. Lennert K, Parwaresch MR: Mast cells and mast cell neoplasia: a review. Histopathology 1979, 3:349-365
2. Metcalfe DD: Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 1991, 96:2S-4S
3. Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, Bennett JM, Metcalfe DD: Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003, 122:695-717
4. Tefferi A, Pardanani A: Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 2004, 11:58-64
5. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995, 92:10560-10564
6. Longley Jr BJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, Heitjan D, Ma Y: Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999, 96:1609-1614
7. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nunez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW, Bennett JM: Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25:603-625
8. Valent P, Horny H-P, Li CY, Longley JB, Metcalfe DD, Parwaresch RM, Bennett JM: Mastocytosis (mast cell disease): Tumours of haematopoietic and lymphoid tissues. Pathology and genetics, vol 1. World Health Organization (WHO) Classification of Tumours. Edited by Jaffe ES, Harris NL, Stein H, Vardiman JW. Geneva, World Health Organization, 2001, pp 291-302
9. Travis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG: Significance of systemic mast cell disease with associated hematologic disorders. Cancer 1988, 62:965-972
10. Sperr WR, Horny HP, Valent P: Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol 2002, 127:140-142
11. Horny H-P, Sotlar K, Sperr WR, Valent P: Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease (SM-AHNMD): a histopathological challenge. J Clin Pathol 2004, 57:604-608
12. Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD: Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000, 28:140-147
13. Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C: Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002, 100:661-665
14. Sotlar K, Fridrich C, Mall A, Jaussi R, Bültmann B, Valent P, Horny H-P: Detection of c-kit point mutation Asp-816Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk Res 2002, 26:979-984
15. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR: Cancer Genome Project: acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061
16. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148
17. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790
18. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland D: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397
19. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981, 29:577-580
20. Sotlar K, Horny H-P, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P: CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) on routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004, 28:1319-1325
21. Sotlar K, Selinka HC, Menton M, Kandolf R, Bültmann B: Detection of human papillomavirus type 16 E6/E7 oncogene transcripts in dysplastic and nondysplastic cervical scrapes by nested RT-PCR. Gynecol Oncol 1998, 69:114-121
22. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y: Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993, 92:1736-1744
23. Simeonov A, Nikiforov TT: Single nucleotide polymorphism genotyping using short, fluorescently labelled locked nucleic acid (LNA) probes and fluorescence polarization detection. Nucleic Acids Res 2002, 30:e91
24. Sotlar K, Escribano L, Landt O, Möhrle S, Herrero S, Torrelo A, Lass U, Horny HP, Bültmann B: One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003, 162:737-746
25. Schütze K, Lahr G: Identification of expressed genes by laser-mediated manipulation of single cells. Nat Biotechnol 1998, 16:737-742
26. Féger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M: Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002, 127:110-114
27. Pullarkat VA, Pullarkat ST, Calverley DC, Brynes RK: Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His. Am J Hematol 2000, 65:307-309
28. Tefferi A, Lasho TL, Brockman SR, Elliott MA, Dispenzieri A, Pardanani A: FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica 2004, 89:871-873
29. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A: CHIC2 deletion, a surrogate for FIP1L1-PDG-FRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003, 102:3093-3096
30. Florian S, Esterbauer H, Binder T, Mullauer L, Haas OA, Sperr WR, Sillaber C, Valent P: Systemic mastocytosis (SM) associated with chronic eosinophilic leukaemia (SM-CEL): detection of FIP1L1/PDG-FRalpha, classification by WHO criteria, and response to therapy with imatinib. Leuk Res 2006, 30:1201-1205
31. Pullarkat V, Bedell V, Kim Y, Bhatia R, Nakamura R, Forman S, Sun J, Senitzer D, Slovak ML: Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res 2007, 31:261-265
32. McClure R, Mai M, Lasho T: Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 2006, 20:168-171
33. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ: The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997, 22:176-181
34. Orum H: PCR clamping. Curr Issues Mol Biol 2000, 2:27-30
35. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA: Creation of human tumour cells with defined genetic elements. Nature 1999, 400:464-468
36. Hahn WC, Weinberg RA: Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002, 2:331-341